Trials / Completed

CompletedNCT00219791

Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance

Study of Recombinant Carboxypeptidase G2 (CPG2) for the Management of Patients With Delayed Methotrexate (MTX) Clearance or Intrathecal MTX Overdosage

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: —

Sponsor: BTG International Inc. · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of glucarpidase in patients with impaired methotrexate (MTX) clearance owing to MTX-induced renal failure following high-dose MTX therapy, or with intrathecal MTX overdose.

Conditions

Neoplasms

Interventions

Type	Name	Description
DRUG	glucarpidase (50 Units/kg)

Timeline

Start date: 2000-01-01
Completion: 2003-06-01
First posted: 2005-09-22
Last updated: 2014-09-11

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00219791. Inclusion in this directory is not an endorsement.